Novo Nordisk is currently leading the market for incretin therapies with semaglutide-based products Ozempic for type 2 ...

The healthcare industry experienced a rollercoaster of a year in 2024, with pharmacy benefits undergoing significant shifts.

Purdue Pharma and the Sackler family who own the company have proposed a new $7.4 billion settlement to resolve thousands of ...

At the top of that list, unsurprisingly, are Novo Nordisk obesity drugs Ozempic, Rybelsus, and Wegovy, all grouped together ...

The new business venture of Spotify founder Daniel Ek – Neko Health – has raised $260 million to bring its full body-scanning ...

AstraZeneca has unveiled plans to invest around $570 million in Canada and add around 700 new jobs, describing the county as ...

The story of HCPs’ advocacy for the Treat and Reduce Obesity Act reveals a broader truth: HCPs care deeply about the ...

Spinraza remains a big product for Biogen, but has seen its sales go into reverse as competition in SMA treatment has emerged ...

SIFI, an Italian ophthalmology company focused mostly on the European market, doesn’t normally make it out to San Francisco ...

One reason is the fact that much research related to ovarian cancer has focused on strategies combining chemotherapy with ...

In fact, a McKinsey study found that “while 90% of companies have launched some flavour of digital transformation, only a ...

People who take weight-loss drugs based on GLP-1 receptor agonists seem to have reduced risk for a litany of diseases, ...